What do systematic reviews say?

Platinum vs non‐platinum therapy

Platinum showed no clear difference in overall survival (OS) compared with non‐platinum regimens (moderate certainty).

• Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only
  HR 0.85 [0.73, 1]
  6 studies · 958 participants
  Moderate

Continuous platinum infusion vs bolus platinum infusion

The review found no eligible studies for this question.

• Different infusion durations for preventing platinum‐induced hearing loss in children with cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Platinum doublet vs non‐platinum therapy

Platinum doublet probably leads to lower overall survival compared with non‐platinum therapy (moderate certainty).

• Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable… 2023 · Cochrane Headline outcomes only
  HR 0.67 [0.57, 0.78]
  7 studies · 697 participants
  Moderate

Non‐platinum therapies vs platinum combination

Non‐platinum therapies probably leads to lower overall survival compared with platinum combination (moderate certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  HR 0.76
  13 studies · 13 participants
  Moderate

Non‐platinum single‐agent vs non‐platinum combination treatment

Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  HR 0.92
  5 studies · 1294 participants
  Low

Taxane‐platinum‐fluoropyrimidine combinations vs taxane‐platinum (without fluoropyrimidine)

It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes overall survival compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).

• Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
  OR 0.86 [0.71, 1.06]
  3 studies · 482 participants
  Very low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with chemotherapy (low certainty).

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.95 [0.62, 1.47]
  2 studies · 331 participants
  Low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.88 [0.65, 1.2]
  2 studies · 560 participants
  Moderate

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  GRADE not reported

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sodium thiosulfate vs no otoprotective intervention

Sodium thiosulfate showed no clear difference in overall survival with intravenous platinum (i.e. mortality/number of… compared with no otoprotective intervention (low certainty).

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  HR 0.43 [0.03, 5.85]
  1 study · 109 participants
  Low

Gemcitabine combinations vs gemcitabine

Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).

• Chemotherapy and radiotherapy for advanced pancreatic cancer 2018 · Cochrane Headline outcomes only
  HR 0.94 [0.81, 1.08]
  6 studies · 1140 participants
  Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.93 [0.83, 1.04]
  5 studies · 2006 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.92 [0.7, 1.21]
  1 study · 242 participants
  Moderate

Summary of findings 2: PLD alone vs other conventional chemotherapy

Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.96 [0.77, 1.19]
  6 studies · 1995 participants
  Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.9 [0.79, 1.02]
  3 studies · 1564 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.86 [0.67, 1.11]
  1 study · 282 participants
  Low

Bevacizumab plus chemotherapy vs chemotherapy alone

Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.73 [0.61, 0.86]
  5 studies · 778 participants
  High

Chemotherapy with TKI vs chemotherapy alone

Chemotherapy with TKI showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.85 [0.68, 1.08]
  8 studies · 940 participants
  Moderate

Leuprorelin vs treosulfan

It is very uncertain whether leuprorelin changes overall survival compared with treosulfan (very low certainty).

• Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
  HR 0.98 [0.58, 1.67]
  Studies not reported
  Very low